Back Home About Us

Do Sex and HIV/HCV Coinfection Affect Response to Antiretroviral Treatment?

HIV-positive men and women coinfected with hepatitis C virus (HCV) showed impaired CD4 T-cell restoration and had a 40% greater risk of death than people with HIV alone, though they were equally likely to achieve HIV viral suppression, according to study findings published in the May 18 advance edition of AIDS Patient Care and STDs.

alt

Read more:

Truvada PrEP Causes Only Minimal Bone Loss, Raltegravir Easier on Bones than PIs

Use of tenofovir/emtricitabine (Truvada) for HIV pre-exposure prophylaxis (PrEP) was associated with a small decrease in bone mineral density that stabilized after the first 6 months, according to study findings reported in the April 23 edition of Clinical Infectious Diseases. Related research showed that HIV-positive people starting an antiretroviral regimen containing the integrase inhibitor raltegravir (Isentress) experienced less bone loss than those taking protease inhibitors.

alt

Read more:

May 18 is HIV Vaccine Awareness Day

May 18 is HIV Vaccine Awareness Day, an annual opportunity to call attention to progress in vaccine science and the need for further research on both preventive vaccines that stop new HIV infections and therapeutic vaccines that help the immune system fight existing infection.

alt

Read more:

First START Results Show Early HIV Treatments Reduces Risk of Illness and Death

Long-awaited interim findings from the START trial have shown that people with HIV who were randomly assigned to start antiretroviral therapy (ART) while their CD4 count was above 500 cells/mm3 had a 53% lower risk of AIDS-related and non-AIDS illnesses and deaths compared to those who waited until their count fell below 350 cells/mm3, according to an announcement today from the National Institute of Allergy and Infectious Diseases.

alt

Read more:

Study Suggests Truvada PrEP Should Start 1 Week Before and Continue 4 Weeks After Sex

An intensive pharmacokinetic study of tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) showed that blood and rectal drugs levels corresponding to high PrEP activity for men who have sex with men (MSM) are reached after about 1 week of daily dosing and appear to remain adequate for several days after the last pill, according to a report in the March 1 edition of Clinical Infectious Diseases. It is not known, however, whether this dosing schedule would work as well for women or other groups.

alt

Read more:

FDA Reduces Gay Blood Donation Ban to 1 Year After Sex, Critics Say It's Still Discriminatory

On May 12 the U.S. Food and Drug Administration (FDA) issued draft guidance stating that men who have sex with men should wait to donate blood until 12 months after their last sexual contact with another man. This is an improvement over the previous policy of lifetime deferral, but some advocates argue that the new regulations still discriminate against gay and bisexual men.

alt

Read more:

BHIVA 2015: People Who Don't Reveal HIV Status Have as Good Health Outcomes as Those Who Do

A large survey of people attending HIV clinics in the UK has found that individuals who chose not to disclose their HIV status to other people were no more likely to suffer from depression or anxiety, to have difficulty adhering to antiretroviral therapy (AR), or to have worse HIV outcomes, according to research presented at the British HIV Association (BHIVA) annual meeting last month in Brighton. 

alt

Read more:

May 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day

Tuesday, May 19, marks the annual observation of National Asian and Pacific Islander HIV/AIDS Awareness Day, an occasion to increase awareness of HIV within these communities and stress the importance of testing, care, and treatment.

alt

Read more:

BHIVA 2015: Undiagnosed HIV Infections Picked Up When Testing People with Other Medical Conditions

A Europe-wide project offering HIV tests to hospital patients with glandular fever symptoms, swollen lymph nodes, a low white blood cell count, a low platelet count, or pneumonia has found that over 3% of tested patients had previously undiagnosed HIV, according to a presentation at the British HIV Association (BHIVA) annual meeting last month in Brighton. This significantly exceeds the level of 0.1% HIV prevalence at which routine HIV testing interventions are considered to be cost-effective. 

alt

Read more: